Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 30, 2022

Avdoralimab (Anti-C5aR1 mAb) vs Placebo in Patients With Severe COVID-19

Critical Care Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

Critical Care Medicine
Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE])
Crit. Care Med. 2022 Oct 11;[EPub Ahead of Print], J Carvelli, F Meziani, J Dellamonica, PY Cordier, J Allardet-Servent, M Fraisse, L Velly, SD Barbar, S Lehingue, C Guervilly, M Desgrouas, F Camou, C Piperoglou, F Vely, O Demaria, J Karakunnel, J Fares, L Batista, F Rotolo, J Viotti, A Boyer-Chammard, K Lacombe, E Le Dault, M Carles, N Schleinitz, E Vivier

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading